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- Neuroblastoma is a childhood neoplasia affecting extracranial 
neuroectodermal tissue and accounting for about 10% of solid 
childhood malignancies, which represents 1/100.000 children 
every year
- Survival rate approach 70%, leading to the emergence of a 
population of adult survivors having been exposed to adverse 
effects of cytotoxic drugs or therapy.
- Adequate management of late effects require appropriate 
awareness and knowledge of them.
- Patients treated for neuroblastoma are exposed to surgery, 
chemotherapy, radiotherapy or MIBG therapy. All those 
treatments potentially affect the endocrine and gonadal system.
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•We retrospectively reviewed medical files of 50 patients (M/F = 
27:23) treated for neuroblastoma between 1994 and 2016.
•Collected data  consisted in age, height, and weight at diagnosis 
as well as age, height, and weight at the time of last endocrine 
follow-up. Standard deviation values were computed for those 
parameters to enable comparison. Biological value such as TSH, 
T4, FSH, LH, ACTH, IGF-1 were recorded at the time of last follow-
up. 
•Incidence of late effect in our sample was compared to 
incidence of late effects due to neuroblastoma therapy in larger 
series.
•Statistical analysis through ANOVA with repeated measures 
(STATISTICA Software) were conducted to study impact of 
chemotherapy on height and weight at follow-up
•Neuroblastoma are divided as either low or high risk, 
depending on age at diagnosis, localization, cytogenetic 
factors and presence of metastasis. Low-risk neuroblastoma 
mainly occur in children below 12 months of age and are often 
managed with surgery only. If localization of tumor makes it 
inoperable, chemotherapy is used as first line of therapy. 
High-risk neuroblastoma therapy require chemotherapy, 
MIBG therapy, radiation therapy, and sometimes autologous 
hemotopoietic stem cell transplant
•In large follow-up series, late effects of neuroblastoma 
therapy affect 89% of patients, and endocrine complications 
affect 62% of female and 45% of males treated for childhood 
neoplasia*. 
•Deafness (55-73%)





TOXICITY BY THERAPEUTICAL AGENTS





- Renal impairment and tubulopathies
- Second malignancies (MDS/leukemia, thyroid)
Radiation therapy
- Ovarian failure
- Leydig cell failure
- Growth deficiency and impaired growth (scoliosis)
- Severe dental abnomalies







•Prepubertal state during therapy protect against ovarian 
failure, which is not always definitive
Growth impact
•Final height is affected in children not treated with TBI, and 
without biological GH deficiency **
•Treatment for childhood malignancies exposes children to 
late effects affecting, among other, the endocrine system. In 
children treated for neuroblastoma, hypothyroidism, gonadal 
failure and altered growth appear as the main complications. 
A close follow-up of survivors is thus highly appropriate.
MATERIAL & METHODS
Our work consists in a retrospective review of endocrine and 
gonadal late effects arising in survivors treated for 
neuroblastoma in childhood.
* Laverdière C, Liu Q, Yasui Y, et al. Long-term Outcomes in Survivors of Neuroblastoma: A Report 
From the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101:1131–1140 
**Cohen LE, Gordon JH, Popovsky EY, et al. Late effects in children treated with intensive 
multimodal therapy fo high-risk neuroblastoma : High incidence of endocrine and growth problems. 
BMT. 2014;49:502-508.
AIM
•Age : Patients included in study were between 0 and 190 months 
old at diagnosis (mean: 27 months) and between 1 and 25 years-
old at follow-up (mean: 11.6 years). 
•Treatment  : 26 patients were treated with chemotherapy, 11 
underwent radiation therapy and 5 were treated with MIBG 
therapy. Others were treated with surgery alone.
•Prognosis and sequelae 
- 5 deceased (10%, 12% in chemotherapy group)
- 4 gonadal dysfunction (male, female) (8%, 16% in 
chemotherapy group)
- 7 hypothyroidism (14% , 20% in chemotherapy, 100% in MIBG)
- Non-endocrine complications
- Partial deafness (n=4), neuropathy (n=1),
- hypogammaglobulinemia (n=3)
- alopecia (n=2),  osteopenia (n=1)
•44% of endocrine complications in chemotherapy group, 18% 
in patients treated with chemotherapy and radiation therapy
RESULTS
Variable N Mean Ecart-type
Age at diagnosis (months) 50 27.3 (0-190) 36.41696
Height at diagnosis (cm) 31 95.2 (49-156) 29.79288
Height at diagnosis SD 31 0.29 (-4.7-4.8) 1.76332
Weight at diagnosis (kg) 35 15.6 (3,095-42) 10.54788
Weight at diagnosis SD 34 -0.007 (-4,1-4,9) 1.50334
BMI at diagnosis 20 16.3 (11.9-21,4) 2.73801
BMI at diagnosis SD 20 -0.44 (-5-1.9) 2.00027
Age at follow-up (years) 27 11.7 (1-25) 6.83161
Height at last follow-up (cm) 28 138.12 (77-181.4) 32.84159
Height at last follow-up SD 27 -0.35 (-4-2) 1.34503
BMI at last follow-up 24 19.23 (13.5-34.7) 5.17372
BMI at last follow-up SD 23 -0.25 (-1.6-2.7) 1.26415
Weight at last follow-up (kg) 27 39.4 (9.33-90) 24.31822
Weight at last follow-up SD 26 -0.16 (-2.7-2.2) 1.25885
Growth rate (cm/year) 14 4.68 (0.9 - 9.9) 2.46707
Growth rate SD 10 -0.09 (-1.3-0.9) 0.75048
DISCUSSION
•There is no effect of chemotherapy on weight at follow up
•There is a significant impact of chemotherapy on height 
after treatment (p<.05, mean of height standard deviation at 
diagnosis = . 0.9 and at follow up = -.59). 
•The effect of chemotherapy on patients’ growth rate 
depended on age at diagnosis (p=.016) (Regression analysis), 
which means that the younger the treatment was started, the 
more severely growth was impacted.
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